{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:17:45Z","timestamp":1764940665941,"version":"3.46.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtct.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:49:33Z","timestamp":1756946973000},"page":"1033.e1-1033.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization of Intravenous Posaconazole in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-5916","authenticated-orcid":false,"given":"Carolyn","family":"Kusoski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parinda A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Markham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D.R.","family":"Setchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Teusink-Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.09.006_bib0001","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1093\/jac\/dkaa377","article-title":"Experience using intravenous posaconazole in paediatric and young adult oncology patients","volume":"75","author":"Lambrix","year":"2020","journal-title":"J Antimicrob Chemother"},{"year":"2022","series-title":"Noxafil (posaconazole) injection, for intravenous use: Prescribing information","key":"10.1016\/j.jtct.2025.09.006_bib0002"},{"key":"10.1016\/j.jtct.2025.09.006_bib0003","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jpids\/piy094","article-title":"Evaluation of intravenous posaconazole dosing and pharmacokinetic target attainment in pediatric patients","volume":"8","author":"Nickless","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jtct.2025.09.006_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13777","article-title":"Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole","volume":"24","author":"Bernardo","year":"2020","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2025.09.006_bib0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40262-023-01254-2","article-title":"Population pharmacokinetics of posaconazole in immunocompromised children and assessment of target attainment in invasive fungal disease","volume":"62","author":"McCann","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2025.09.006_bib0006","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/MPH.0000000000001071","article-title":"Use of intravenous posaconazole in hematopoietic stem cell transplant patients","volume":"40","author":"Strommen","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2025.09.006_bib0007","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.bbmt.2016.12.150","article-title":"Intravenous posaconazole is safe and effective in pediatric HSCT patients","volume":"23","author":"Teusink-Cross","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.006_bib0008","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of Torsade de Pointes in hospital settings","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jtct.2025.09.006_bib0009","unstructured":"Woosley RL, Heise CW, Gallo T et al. www.CredibleMeds.org, QTdrugs List. Accessed August 30, 2023. AZCERT, Inc. 1457 E Desert Garden Dr, Tucson, AZ 85718"},{"key":"10.1016\/j.jtct.2025.09.006_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.kint.2016.03.031","article-title":"A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury","volume":"90","author":"Goldstein","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtct.2025.09.006_bib0011","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/ijms17020224","article-title":"Hepatotoxicity by drugs: the most common implicated agents","volume":"17","author":"Bjornsson","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.006_bib0012","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.09.006_bib0013","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/myc.12948","article-title":"Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations","volume":"62","author":"Martson","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.jtct.2025.09.006_bib0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.006_bib0015","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.09.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106084","article-title":"Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial","volume":"56","author":"Groll","year":"2020","journal-title":"Int J Antimicrob Agents"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:15:37Z","timestamp":1764940537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666636725014095"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of Intravenous Posaconazole in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}